期刊文献+

复方阿嗪米特联合复合乳酸菌胶囊治疗腹泻型肠易激综合征临床疗效观察 被引量:4

Clinical Observation on Compound Azintamide Enteric Coated Tablet Combined with Lactobacillus Complex Capsule in the Treatment of Diarrhea-Predominant Pattern Irritable Bowel Syndrome
下载PDF
导出
摘要 目的:观察复方阿嗪米特联合复合乳酸菌胶囊治疗腹泻型肠易激综合征(IBS)的临床疗效。方法将108例腹泻型IBS患者随机分为治疗组(A组,n=54)和对照组(B组,n=54)。A组给予复方阿嗪米特肠溶片联合复合乳酸菌胶囊口服。B组采用复合乳酸菌胶囊口服。2组均治疗4周后观察疗效。结果总有效率A组为87.0%,B组64.8%,差异有统计学意义(P<0.05)。结论复方阿嗪米特联合复合乳酸菌胶囊治疗腹泻型IBS较单纯复合乳酸菌胶囊疗效更为显著,值得进一步研究和临床推广。 Objective To investigate the curative effect of compound azintamide enteric coated tablet combined with lactobacillus complex capsule for diarrhea-predominant pattern irritable bowel syndrome. Methods 108 patients with diarrhea-predominant pattern irritable bowel syndrome were randomized into treatment group (n=54, group A, treated with compound azintamide enteric coated tablet combined with lactobacillus complex capsule), and control group (n=54, group B, treated with lactobacillus complex capsule only). The two groups were treated for four weeks, and the curative effects were observed. Results The total effective rate were 87.0%in group A, and 64.8%in group B with significant difference (P〈0.05). Conclusion The curative effect of compound azintamide enteric coated tablet combined with lactobacillus complex capsule was more significant than that of lactobacillus complex capsule used alone. It is worthy of further research and clinical promotion.
作者 许静亚
出处 《中国血液流变学杂志》 CAS 2014年第2期235-236,267,共3页 Chinese Journal of Hemorheology
关键词 复方阿嗪米特 复合乳酸菌胶囊 腹泻型肠易激综合征 compound azintamide lactobacillus complex capsule diarrhea-predominant pattern irritable bowel syndrome
  • 相关文献

参考文献8

二级参考文献71

  • 1卢若丽.肠易激综合征的诊治进展[J].大理学院学报(综合版),2005,4(z1):92-94. 被引量:2
  • 2王宏,卢晓洁,王志超.培菲康联合得舒特治疗肠易激惹综合征的疗效观察[J].国际医药卫生导报,2006,12(24):73-75. 被引量:2
  • 3[1]Lauer GM,Walker BD.Hepatitis C virus infection.N Engl J Med 2001; 345:41-52.
  • 4[2]Alter MJ,Kruszon-Moran D,Nainan OV,McQuillan GM,Gao F,Moyer LA,Kaslow RA,Margolis HS.The prevalence of hepatitis C virus infection in the United States,1988 through 1994.N Engl J Med 1999; 341:556-562
  • 5[3]Curry MP.Hepatitis B and hepatitis C viruses in liver transplantation.Transplantation 2004; 78:955-963
  • 6[4]Vargas HE,Laskus T,Radkowski M,Wilkinson J,Balan V,Douglas DD,Harrison ME,Mulligan DC,Olden K,Adair D,Rakela J.Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation.Liver Transpl 2002; 8:1014-1019
  • 7[5]Yan FM,Chen AS,Hao F,Zhao XP,Gu CH,Zhao LB,Yang DL,Hao LJ.Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C.World J Gastroenterol 2000; 6:805-811
  • 8[6]Lamelin JP,Zoulim F,Trepo C.Lymphotropism of hepatitis B and C viruses:an update and a newcomer.Int J Clin Lab Res 1995; 25:1-6
  • 9[7]Gruener NH,Jung MC,Schirren CA.Recurrent hepatitis C virus infection after liver transplantation:natural course,therapeutic approach and possible mechanisms of viral control.J Antimicrob Chemother 2004; 54:17-20
  • 10[8]Porter SB,Reddy KR.Factors that influence the severity of recurrent hepatitis C virus following liver transplantation.Clin Liver Dis 2003; 7:603-614

共引文献577

同被引文献39

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部